Prilenia

Prilenia

Biotechnology, 8 Curtis Dr, Boston, Massachusetts, 08822, United States, 11-50 Employees

prilenia.com

  • twitter
  • LinkedIn

phone no Phone Number: +31*********

Who is PRILENIA

Prilenia is a clinical-stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders. Our lead asset is Pridopidine, a first-in-class...

Read More

map
  • 8 Curtis Dr, Boston, Massachusetts, 08822, United States Headquarters: 8 Curtis Dr, Boston, Massachusetts, 08822, United States
  • 2018 Date Founded: 2018
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2834 | NAICS Code: 54 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from PRILENIA

Prilenia Org Chart and Mapping

Employees

Christine Syltevik

Senior Director Clinical Operations

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Prilenia

Answer: Prilenia's headquarters are located at 8 Curtis Dr, Boston, Massachusetts, 08822, United States

Answer: Prilenia's phone number is +31*********

Answer: Prilenia's official website is https://prilenia.com

Answer: Prilenia's revenue is $1 Million to $5 Million

Answer: Prilenia's SIC: 2834

Answer: Prilenia's NAICS: 54

Answer: Prilenia has 11-50 employees

Answer: Prilenia is in Biotechnology

Answer: Prilenia contact info: Phone number: +31********* Website: https://prilenia.com

Answer: Prilenia is a clinical-stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders. Our lead asset is Pridopidine, a first-in-class oral drug candidate with an established safety profile and potential in multiple movement disorders and neurodegenerative diseases affecting adults and children. Pridopidine is currently being evaluated for the treatment of Huntingtons disease in our global Phase 3 PROOF-HD trial, and for the treatment of ALS in the Phase 2/3 HEALEY platform trial. The company is led by Dr. Michael Hayden, MD, PhD, the founder of five biotech companies and previous President of Global R&D and Chief Scientific Officer at Teva. Michael has directed the development of multiple innovative drug products, leading to 35 approvals between 2012-2018. The Company is based in Naarden, the Netherlands, Herzliya, Israel and Boston, MA in the U.S.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access